Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix to Report Financial Results for Q3

June 23, 2022
RNS Number : 8594P Renalytix PLC 23 June 2022       Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30   NEW YORK and SALT LAKE CITY , June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022

Mount Sinai clinical utility data

June 10, 2022
RNS Number : 4139O Renalytix PLC 10 June 2022     Renalytix plc ("Renalytix" or the "Company")   1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification  in Stage 1 to 3 Diabetic Kidney Disease Patients   Late-breaking data presented at American

Renalytix to Present at Growth Stock Conference

June 8, 2022
RNS Number : 0740O Renalytix PLC 08 June 2022       Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference   NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth

KidneyIntelX data shows ability to assess risk

June 6, 2022
RNS Number : 6872N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort   Data shared in oral presentation at American

Data Presentations at ADA 82nd Scientific Sessions

June 6, 2022
RNS Number : 6870N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix held Two Data Presentations on KidneyIntelX at American Diabetes Association 82 nd Scientific Sessions®   Real-world clinical utility in 1,112 patients tested with   KidneyIntelX KidneyIntelX

Total Voting Rights

April 29, 2022
RNS Number : 9425J Renalytix PLC 29 April 2022   Renalytix plc   (" Renalytix " or the " Company ")     Total voting rights   NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence

Grant of Share Options

April 22, 2022
RNS Number : 9726I Renalytix PLC 22 April 2022     Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   New York and SALT LAKE CITY , April  22, 2022   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total

Successful completion of $30.0m financing package

April 8, 2022
RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

Issue of shares

April 8, 2022
RNS Number : 7218H Renalytix PLC 08 April 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new

$30.0 million financing package

March 31, 2022
RNS Number : 7325G Renalytix PLC 31 March 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR
Displaying 1 - 10 of 203